RSS   Newsletter   Contact   Advertise with us
Post Online Media

Impax adds J. Kevin Buchi to board of directors

J Kevin BuchiImpax Laboratories, a specialty pharmaceutical company, announced that J. Kevin Buchi was appointed to the Impax board of directors.

Mr. Buchi currently serves as President, Chief Executive Officer and a member of the board of directors of TetraLogic Pharmaceuticals Corporation.

Article continues below

READ MORE Impax names Douglas S. Boothe president of generics division

Prior to joining TetraLogic Pharmaceuticals in August 2013, Mr. Buchi served as Corporate Vice President of Global Branded Products at Teva Pharmaceutical Industries Limited from 2011 to May 2012.

Before joining Teva, he was Chief Executive Officer of Cephalon, Inc., which was acquired by Teva in October 2011.

Mr. Buchi joined Cephalon in 1991 and held various leadership positions, including Chief Financial Officer and Chief Operating Officer, before becoming Cephalon's Chief Executive Officer in December 2010.

In addition to being a director of TetraLogic Pharmaceuticals, Mr. Buchi has since 2013 served as a director of Benitec Biopharma Ltd., a NASDAQ listed biotechnology company headquartered in Australia.

He has extensive experience as a director having previously served on the board of a number of pharmaceutical companies including EPIRUS Biopharmaceuticals, Inc., Alexza Pharmaceuticals, Inc. and Forward Pharma A/S.

Mr. Buchi received his B.A. degree in Chemistry from Cornell University and a Masters of Management degree from the J.L. Kellogg Graduate School of Management, Northwestern University.




What to read next



 LATEST MOVES FROM California 





More inside POST
 
 

We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy